

Supplementary Table S1. Detailed search strategy.

Database	Keywords	Record identified
ClinicalTrials.gov	'pulmonary vein isolation'	199
	'second-generation cryoballoon'	1
	'2nd generation cryoballoon'	1
	'contact force radiofrequency'	12
	'contact force-sensing radiofrequency'	5
Cochrane	('ablation' OR 'catheter ablation') AND ('pulmonary vein isolation' OR 'PVI') AND ('second-generation cryoballoon' OR '2nd generation cryoballoon') AND ('contact force radiofrequency' OR 'contact force-sensing radiofrequency') AND ('paroxysmal atrial fibrillation' OR 'paroxysmal AF')	9
ProQuest	('ablation' OR 'catheter ablation') AND ('pulmonary vein isolation' OR 'PVI') AND ('second-generation cryoballoon' OR '2nd generation cryoballoon') AND ('contact force radiofrequency' OR 'contact force-sensing radiofrequency') AND ('paroxysmal atrial fibrillation' OR 'paroxysmal AF')	290
PubMed	('ablation' OR 'catheter ablation') AND ('pulmonary vein isolation' OR 'PVI') AND ('second-generation cryoballoon' OR '2nd generation cryoballoon') AND ('contact force radiofrequency' OR 'contact force-sensing radiofrequency') AND ('paroxysmal atrial fibrillation' OR 'paroxysmal AF')	22
ScienceDirect	('ablation' OR 'catheter ablation') AND ('pulmonary vein isolation' OR 'PVI') AND ('second-generation cryoballoon' OR '2nd generation cryoballoon') AND ('contact force radiofrequency' OR 'contact force-sensing radiofrequency') AND ('paroxysmal atrial fibrillation' OR 'paroxysmal AF')	204
Other source	Potentially relevant papers from the reference lists of the examined articles	9

AF = atrial fibrillation; PVI = pulmonary vein isolation

Supplementary Table S2. Modified Jadad Scale.

Author	Was the study described as randomized?	Was the method of randomization appropriate?	Was the study described as blinding?	Was the method of blinding appropriate?	Was there a description of withdrawals and dropouts?	Was there a clear description of the inclusion/exclusion criteria?	Was the method used to assess adverse effects described?	Were the methods of statistical analysis described?	Modified Jadad scale
Giannopoulos, et al, 2019	1	1	0.5	1	0	1	1	1	6.5
Gunawardene, et al, 2018	1	1	0	0	1	1	1	1	6
Watanabe, et al, 2018	1	1	0	0	0	1	1	1	5

Supplementary Table S3. Methodological index for non-randomized studies.

Author	A clearly stated aim	Inclusion of consecutive patients	Prospective collection of data	Endpoints appropriate to the aim the of study	Unbiased assessment of the study endpoint	Follow-up period appropriate to the aim of the study	The loss to follow up <5%	Prospective calculation of study size	An adequate control group	Contemporary group	Baseline equivalence of groups	Adequate statistical analysis	MINORS
Hassan, et al, 2020	2	2	2	2	0	2	2	0	2	2	1	2	19
Hisazaki, et al, 2019	2	2	0	2	0	2	2	0	2	2	2	2	18
Jourda, et al, 2015	2	2	2	2	0	2	0	2	2	2	1	2	19
Kardos, et al, 2016	2	1	2	2	0	2	2	0	2	2	2	2	19
Matta, et al, 2018	2	2	2	2	0	2	0	0	2	2	2	2	18
Squara, et al, 2015	2	2	1	2	0	2	0	0	2	2	2	2	17
Tanaka, et al, 2019	2	2	0	2	0	2	2	2	2	2	2	2	20
Xiao, et al, 2020	2	2	0	2	0	2	0	2	2	2	1	2	17
Yokokawa, et al, 2017	2	2	0	2	0	2	2	0	2	2	1	2	17

MINORS = methodological index for non-randomized studies.